Quarterly ResultAug 12, 2026, 04:06 PM
Spero Therapeutics Gets FDA Approval for Utebzi; Licenses SP001
AI Summary
Spero Therapeutics announced Q2 2026 financial results and significant corporate updates. The company received U.S. FDA approval for Utebzi™ (tebipenem pivoxil) for complicated urinary tract infections in June 2026. Additionally, Spero entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready antibody for immune-mediated diseases, and secured $105 million in non-dilutive royalty financing, extending its cash runway into the second half of 2029. For Q2 2026, Spero reported a net loss of $9.6 million with no revenue, compared to a net loss of $1.7 million and $14.2 million in revenue in Q2 2025. The company also appointed Debra Zack as Chief Medical Officer.
Key Highlights
- U.S. FDA approved Utebzi™ (tebipenem pivoxil) for cUTIs in June 2026.
- Entered exclusive license agreement for SP001 with Innovent Biologics in July 2026.
- Closed $105 million non-recourse, non-dilutive royalty financing in July 2026.
- Financing extends cash runway into the second half of 2029.
- Reported Q2 2026 net loss of $9.6 million, compared to $1.7 million in Q2 2025.
- Q2 2026 revenue was $0, down from $14.2 million in Q2 2025.
- Appointed Debra Zack, M.D., Ph.D., as Chief Medical Officer in July 2026.
Price Impact
More from SPRO